Unraveling the synergistic potential of naringenin as an Aβ fibrillation inhibitor with metal chelating and antioxidant properties.
Abstract
Alzheimer's disease (AD) is a fatal, multifaceted degenerative brain disorder characterized by amyloid-β (Aβ) fibrillation leading to the formation of neurotoxic oligomers and fibrils, metal ion dysregulation, and oxidative stress, all of which contribute to its pathophysiology. Naringenin (NAR), a flavonoid isolated from citrus fruits, has been identified as a potential therapeutic agent for AD, due to its ability to cross the blood-brain barrier (BBB) and modulate key pathogenic processes. In this work, the synergistic potential of NAR to modulate Aβ42 fibrillation, disaggregate preformed Aβ42 fibrils, metal-induced Aβ42 fibrillation, and oxidative stress was examined using various biophysical techniques. Notably, NAR effectively inhibits Aβ42 fibrillation (96.6 ± 0.2% inhibition at a 1 : 4 ratio of Aβ42 : NAR), with an IC50 value of 9.62 ± 0.14 µM, and disrupts preformed Aβ42 fibrils by 85.1 ± 1.0%. NAR shows antioxidant properties and thus halts the formation of reactive oxygen species (ROS). Notably, NAR restored 94.1 ± 4.7% of the tyrosine fluorescence at 20 µM concentration, suggesting its potential to extract metal from the Aβ42-Cu2+ complex and thus mitigate Cu2+-induced Aβ42 toxicity. Importantly, at doses up to 100 µM, NAR shows nearly 90% cell viability in PC12 cells, highlighting its safety profile and alleviating the cytotoxicity induced by Aβ42 aggregates. Furthermore, molecular dynamics (MD) simulations highlighted favourable binding of NAR to Aβ42 protofibrils (ΔGfit = -12.85 ± 1.21 kcal mol-1), resulting in overall structural deformation of the anti-parallel β-sheet-rich Aβ42 protofibrils. Importantly, NAR-induced lowering in the β-sheet content with an associated rise in the coil content was noted in the Aβ42 protofibrils, consistent with ThT, CD, and TEM assays depicting NAR-mediated disassembly of pre-existing Aβ42 fibrils. The study highlights the potential of NAR as a multifunctional ligand, targeting Aβ42 fibrillation, metal-induced Aβ42 fibrillation, and oxidative stress. Furthermore, MD simulations in this work illuminated the molecular mechanism by which NAR disrupts the Aβ42 protofibril structure, which will provide key insights into the rational design and development of potent therapeutics against the disruption of neurotoxic β-sheet-rich Aβ42 aggregates in AD.